At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SXTP 60 degrees pharmaceuticals, Inc.
Halted 01-16 16:00:00 EST
0.6100
+0.1444
+31.01%
盘后0.5941
-0.0159-2.61%
19:49 EST
High0.6771Low0.4700Vol3.29M
Open0.4853D1 Closing0.4656Amplitude44.48%
Mkt Cap2.58MTradable Cap2.24MTotal Shares4.23M
T/O1.83MT/O Rate89.74%Tradable Shares3.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

60 Degrees Pharmaceuticals Inc trading halted, news pending
TIPRANKS  ·  01-17 08:50
60 Degrees Pharmaceuticals Inc trading halted, news pending
BRIEF-60 Degrees Pharmaceuticals, Inc. Announces Approval Of Reverse Stock Split Ratio
Reuters  ·  01-15
BRIEF-60 Degrees Pharmaceuticals, Inc. Announces Approval Of Reverse Stock Split Ratio
60 Degrees Pharmaceuticals Announces 1-for-4 Reverse Stock Split
Reuters  ·  01-15
60 Degrees Pharmaceuticals Announces 1-for-4 Reverse Stock Split
60 Degrees Pharma outlines growth strategy in investor webinar
TIPRANKS  ·  01-08
60 Degrees Pharma outlines growth strategy in investor webinar
60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue
Reuters  ·  2025-12-29
60 Degrees Pharmaceuticals Launches B-Free Study to Evaluate Tafenoquine for Chronic Babesiosis Fatigue
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting With Chronic Fatigue in Peer-Reviewed, Sponsored Study at Nc State
THOMSON REUTERS  ·  2025-12-29
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting With Chronic Fatigue in Peer-Reviewed, Sponsored Study at Nc State
Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc
Reuters  ·  2025-12-17
Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc
Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc
Reuters  ·  2025-12-12
Geoffrey S. Dow, President and CEO, Acquires Common Shares of 60 Degrees Pharmaceuticals Inc
BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026
Reuters  ·  2025-12-11
BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026
60 Degrees Pharmaceuticals Announces Expansion of Arakoda® Sales and Marketing in 2026
THOMSON REUTERS  ·  2025-12-11
60 Degrees Pharmaceuticals Announces Expansion of Arakoda® Sales and Marketing in 2026
60 Degrees Pharmaceuticals Inc - to Add Clinical Sites for Babesiosis Trials
THOMSON REUTERS  ·  2025-12-11
60 Degrees Pharmaceuticals Inc - to Add Clinical Sites for Babesiosis Trials
60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  2025-11-28
60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital
BRIEF-60 Degrees Pharmaceuticals Announces Clinical Site Now Open For Patient Enrollment
Reuters  ·  2025-11-21
BRIEF-60 Degrees Pharmaceuticals Announces Clinical Site Now Open For Patient Enrollment
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
GlobeNewswire  ·  2025-11-21
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts
TIPRANKS  ·  2025-11-18
60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TIPRANKS  ·  2025-11-17
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharm Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones  ·  2025-11-14
60 Degrees Pharm Coverage Assumed by HC Wainwright & Co. at Buy
60 Degrees Q3 EPS $(0.66) Beats $(1.21) Estimate, Sales $437.602K Beat $400.000K Estimate
Benzinga  ·  2025-11-14
60 Degrees Q3 EPS $(0.66) Beats $(1.21) Estimate, Sales $437.602K Beat $400.000K Estimate
60 Degrees Pharmaceuticals Q3 Operating Expenses USD 2.32 Million
THOMSON REUTERS  ·  2025-11-14
60 Degrees Pharmaceuticals Q3 Operating Expenses USD 2.32 Million
60 Degrees Pharmaceuticals Q3 Net Income USD -2.44 Million
THOMSON REUTERS  ·  2025-11-14
60 Degrees Pharmaceuticals Q3 Net Income USD -2.44 Million

Introduction

Company Name.
60 degrees pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.
Issue price:
--